Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 15;17:189. doi: 10.1186/s12974-020-01847-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 6 — Lack of significant differences in selected lymphocyte subsets stratified for patients with active and stable disease activity during the 48-month study period. Each row represents data from one lymphocyte subset, with the left panels in each row illustrating between-subjects analyses, followed by within-subjects analyses for patients with active (middle panels) and stable (right panels) disease activity. a–c Changes in CD4+CD25+CD127+foxP3- Teff. d–f Changes in CD4+CD25^hiCD127^lo/neg foxP3+ Tregs. g–i Changes in CD19+CD20+CD27- total naïve B cells. j–l Changes in CD19+CD20+CD27-CD24^hi CD38^hi B cells. m–o Changes in CD3-CD56^bright NK cells. p–r Changes in CD3+CD56+ NKT cells. Data represent median/IQR; closed symbols indicate patients with active disease, and open symbols indicate patients with stable disease. Data were subjected to between- and within-subject analyses using a linear mixed effects model for repeated measures